A Randomized, Double-blind, placebo-controlled, two-part study in Parkinson's disease patients with dyskinesia
Date Published March 17, 2026
A randomized, double-blind, placebo-controlled trial assessing JM-010 combinations for Parkinson's dyskinesia safety and efficacy.
| This research brief describes a randomized, double-blind, placebo-controlled, two-part clinical study in patients with Parkinson’s disease who experience dyskinesia, designed to assess the efficacy and safety/tolerability of fixed-dose combinations that include JM-010. The study’s randomized, double-blind, placebo-controlled framework indicates a commitment to minimizing bias and obtaining reliable estimates of treatment effect. A two-part structure commonly allows initial evaluation of dose, safety, or proof-of-concept in an early phase followed by an expanded efficacy and tolerability assessment; in this case, the trial evaluates fixed-dose combinations that include JM-010, focusing on both therapeutic benefit for dyskinesia and the safety and tolerability profile of these combinations in the Parkinson’s population. The dual focus on efficacy and safety/tolerability recognizes the clinical imperative in Parkinson’s care to balance symptomatic benefit with adverse effects that can diminish quality of life. By testing fixed-dose combinations, the study aims to determine whether specific, predefined formulations deliver consistent effects and acceptable safety, which could simplify dosing strategies and improve adherence if successful. |
COM Affiliation
Funding Type
Corporate Grant (for-profit and non-profit)
Update This Listing
Help us provide the most up-to-date information about this project.
Contact UsQuestions?
For questions about these research projects please email us.
Contact Us